Analysts Set Cellebrite DI Ltd. (NASDAQ:CLBT) PT at $20.29

Cellebrite DI Ltd. (NASDAQ:CLBT) has been given a consensus rating of “Buy” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the stock in the last year is $20.57.

A number of brokerages recently issued reports on CLBT. TD Cowen increased their target price on Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. JPMorgan Chase & Co. increased their target price on Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday. Craig Hallum increased their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Needham & Company LLC raised their price objective on Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

Hedge Funds Weigh In On Cellebrite DI

Several large investors have recently bought and sold shares of the stock. FMR LLC increased its position in shares of Cellebrite DI by 136.3% during the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock valued at $94,586,000 after purchasing an additional 3,239,307 shares during the last quarter. Principal Financial Group Inc. purchased a new stake in shares of Cellebrite DI during the 3rd quarter valued at $23,402,000. Pembroke Management LTD increased its position in shares of Cellebrite DI by 104.9% during the 2nd quarter. Pembroke Management LTD now owns 1,535,726 shares of the company’s stock valued at $18,352,000 after purchasing an additional 786,310 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Cellebrite DI during the 3rd quarter valued at $11,523,000. Finally, Summit Partners Public Asset Management LLC purchased a new stake in shares of Cellebrite DI during the 3rd quarter valued at $9,274,000. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Stock Down 0.3 %

Shares of CLBT opened at $20.23 on Friday. Cellebrite DI has a 12-month low of $7.91 and a 12-month high of $21.72. The business’s fifty day moving average is $19.02 and its 200 day moving average is $15.95. The stock has a market cap of $4.17 billion, a P/E ratio of -13.05, a P/E/G ratio of 2.71 and a beta of 1.51.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company had revenue of $106.90 million for the quarter, compared to analysts’ expectations of $102.06 million. During the same period last year, the business earned $0.09 EPS. Cellebrite DI’s quarterly revenue was up 27.0% compared to the same quarter last year. On average, analysts expect that Cellebrite DI will post 0.32 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.